FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2172291581> ?p ?o ?g. }

• W2172291581 endingPage "323" @default.
• W2172291581 startingPage "318" @default.
• W2172291581 abstract "Background. Mycophenolate mofetil (MMF) has been shown to decrease the incidence of acute rejection episodes after kidney transplantation. The use of MMF along with tacrolimus for ≥1 year after pancreas transplantation has not been studied in a large single-center analysis. Methods. Between July 1, 1995 and June 30, 1997, both MMF and tacrolimus were given to 120 pancreas transplant recipients. By category, 61 underwent simultaneous pancreas-kidney transplantation (SPK); 44 underwent pancreas transplantation after previous kidney transplantation (PAK); and 15 underwent pancreas transplantation alone (PTA). By donor source, 86% of the grafts were from a cadaver, and 14% were from a living-related donor. Induction therapy was with MMF, tacrolimus, prednisone, and antithymocyte globulin (n=109) or OKT3 (n=2). Until oral intake was resumed, recipients initially received intravenous azathioprine. Side effects were as follows: gastrointestinal (GI) toxicity in 53% of recipients receiving combined MMF and tacrolimus therapy; bone marrow toxicity in 24% of recipients receiving MMF alone; nephrotoxicity in 18% and neurotoxicity in 11% of recipients receiving tacrolimus alone. We did a matched-pair analysis to compare outcome in MMF versus azathioprine recipients, using the database of the International Pancreas Transplant Registry. Matching criteria included transplantation category, transplantation number, recipient and donor age, duct management, HLA typing, and transplantation year. Results. One-year patient survival rates were 98% for SPK, 98% for PAK, and 100% for PTA (P=NS). For SPK recipients, 1-year pancreas graft survival rates were 86% with MMF versus 79% with azathioprine (P=NS); kidney graft survival rates were 96% with MMF versus 86% with azathioprine(P=NS). The incidence of first rejection episodes at 1 year was significantly lower for MMF recipients (15% with MMF versus 43% with azathioprine) (P=0.0003). For recipients of solitary pancreas transplants (PTA and PAK), we found no difference in graft survival rates between MMF and azathioprine. The conversion rate from MMF to azathioprine at 1 year was 14% for SPK recipients, 26% for PAK, and 39% for PTA(P<0.007). The most common reason for conversion was GI toxicity, in particular for nonuremic (PTA) or posturemic (PAK) recipients. The rates of posttransplant infection and lymphoproliferative disease were low for recipients on MMF and tacrolimus. Conclusions. The combination of MMF and tacrolimus after pancreas transplantation is highly effective and safe. For SPK recipients, the incidence of acute reversible rejection episodes was significantly lower with MMF than with azathioprine. The conversion rate from MMF to azathioprine because of GI toxicity was lowest for SPK and highest for PTA recipients." @default.
• W2172291581 created "2016-06-24" @default.
• W2172291581 creator A5002231208 @default.
• W2172291581 creator A5009112502 @default.
• W2172291581 creator A5030109410 @default.
• W2172291581 creator A5058349284 @default.
• W2172291581 creator A5084314786 @default.
• W2172291581 creator A5086360508 @default.
• W2172291581 date "1998-08-01" @default.
• W2172291581 modified "2023-09-29" @default.
• W2172291581 title "MYCOPHENOLATE MOFETIL IN PANCREAS TRANSPLANTATION" @default.
• W2172291581 cites W1966161368 @default.
• W2172291581 cites W1970784572 @default.
• W2172291581 cites W1972942401 @default.
• W2172291581 cites W2016273346 @default.
• W2172291581 cites W2023572139 @default.
• W2172291581 cites W2044245059 @default.
• W2172291581 cites W2054880628 @default.
• W2172291581 cites W2060661326 @default.
• W2172291581 cites W2150064963 @default.
• W2172291581 cites W2336236972 @default.
• W2172291581 cites W2609602266 @default.
• W2172291581 cites W4230996310 @default.
• W2172291581 cites W50336179 @default.
• W2172291581 doi "https://doi.org/10.1097/00007890-199808150-00007" @default.
• W2172291581 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9721799" @default.
• W2172291581 hasPublicationYear "1998" @default.
• W2172291581 type Work @default.
• W2172291581 sameAs 2172291581 @default.
• W2172291581 citedByCount "64" @default.
• W2172291581 countsByYear W21722915812012 @default.
• W2172291581 countsByYear W21722915812014 @default.
• W2172291581 countsByYear W21722915812017 @default.
• W2172291581 countsByYear W21722915812018 @default.
• W2172291581 countsByYear W21722915812020 @default.
• W2172291581 countsByYear W21722915812021 @default.
• W2172291581 countsByYear W21722915812022 @default.
• W2172291581 countsByYear W21722915812023 @default.
• W2172291581 crossrefType "journal-article" @default.
• W2172291581 hasAuthorship W2172291581A5002231208 @default.
• W2172291581 hasAuthorship W2172291581A5009112502 @default.
• W2172291581 hasAuthorship W2172291581A5030109410 @default.
• W2172291581 hasAuthorship W2172291581A5058349284 @default.
• W2172291581 hasAuthorship W2172291581A5084314786 @default.
• W2172291581 hasAuthorship W2172291581A5086360508 @default.
• W2172291581 hasBestOaLocation W21722915811 @default.
• W2172291581 hasConcept C126322002 @default.
• W2172291581 hasConcept C126894567 @default.
• W2172291581 hasConcept C141071460 @default.
• W2172291581 hasConcept C2776760755 @default.
• W2172291581 hasConcept C2778064082 @default.
• W2172291581 hasConcept C2778720950 @default.
• W2172291581 hasConcept C2779134260 @default.
• W2172291581 hasConcept C2780303639 @default.
• W2172291581 hasConcept C2909675724 @default.
• W2172291581 hasConcept C2911091166 @default.
• W2172291581 hasConcept C71924100 @default.
• W2172291581 hasConcept C90924648 @default.
• W2172291581 hasConceptScore W2172291581C126322002 @default.
• W2172291581 hasConceptScore W2172291581C126894567 @default.
• W2172291581 hasConceptScore W2172291581C141071460 @default.
• W2172291581 hasConceptScore W2172291581C2776760755 @default.
• W2172291581 hasConceptScore W2172291581C2778064082 @default.
• W2172291581 hasConceptScore W2172291581C2778720950 @default.
• W2172291581 hasConceptScore W2172291581C2779134260 @default.
• W2172291581 hasConceptScore W2172291581C2780303639 @default.
• W2172291581 hasConceptScore W2172291581C2909675724 @default.
• W2172291581 hasConceptScore W2172291581C2911091166 @default.
• W2172291581 hasConceptScore W2172291581C71924100 @default.
• W2172291581 hasConceptScore W2172291581C90924648 @default.
• W2172291581 hasIssue "3" @default.
• W2172291581 hasLocation W21722915811 @default.
• W2172291581 hasLocation W21722915812 @default.
• W2172291581 hasLocation W21722915813 @default.
• W2172291581 hasOpenAccess W2172291581 @default.
• W2172291581 hasPrimaryLocation W21722915811 @default.
• W2172291581 hasRelatedWork W1976338908 @default.
• W2172291581 hasRelatedWork W2009223252 @default.
• W2172291581 hasRelatedWork W2085610405 @default.
• W2172291581 hasRelatedWork W2094281457 @default.
• W2172291581 hasRelatedWork W2172291581 @default.
• W2172291581 hasRelatedWork W2390858815 @default.
• W2172291581 hasRelatedWork W2402564018 @default.
• W2172291581 hasRelatedWork W2430221043 @default.
• W2172291581 hasRelatedWork W3140081348 @default.
• W2172291581 hasRelatedWork W4237896243 @default.
• W2172291581 hasVolume "66" @default.
• W2172291581 isParatext "false" @default.
• W2172291581 isRetracted "false" @default.
• W2172291581 magId "2172291581" @default.
• W2172291581 workType "article" @default.